[1]
Reid IR,Green JR,Lyles KW,Reid DM,Trechsel U,Hosking DJ,Black DM,Cummings SR,Russell RGG,Eriksen EF, Zoledronate. Bone. 2020 Aug;
[PubMed PMID: 32353565]
[2]
Camacho PM,Petak SM,Binkley N,Diab DL,Eldeiry LS,Farooki A,Harris ST,Hurley DL,Kelly J,Lewiecki EM,Pessah-Pollack R,McClung M,Wimalawansa SJ,Watts NB, AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2020 May;
[PubMed PMID: 32427503]
Level 1 (high-level) evidence
[3]
Qaseem A,Forciea MA,McLean RM,Denberg TD,Clinical Guidelines Committee of the American College of Physicians.,Barry MJ,Cooke M,Fitterman N,Harris RP,Humphrey LL,Kansagara D,McLean RM,Mir TP,Schünemann HJ, Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. Annals of internal medicine. 2017 Jun 6;
[PubMed PMID: 28492856]
Level 1 (high-level) evidence
[4]
Chotiyarnwong P, McCloskey EV. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nature reviews. Endocrinology. 2020 Aug:16(8):437-447. doi: 10.1038/s41574-020-0341-0. Epub 2020 Apr 14
[PubMed PMID: 32286516]
[5]
Kravets I, Paget's Disease of Bone: Diagnosis and Treatment. The American journal of medicine. 2018 Nov;
[PubMed PMID: 29752905]
[6]
Chakhtoura M,El-Hajj Fuleihan G, Treatment of Hypercalcemia of Malignancy. Endocrinology and metabolism clinics of North America. 2021 Dec;
[PubMed PMID: 34774248]
[7]
Anderson K,Ismaila N,Flynn PJ,Halabi S,Jagannath S,Ogaily MS,Omel J,Raje N,Roodman GD,Yee GC,Kyle RA, Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Mar 10;
[PubMed PMID: 29341831]
Level 1 (high-level) evidence
[8]
von Moos R,Sternberg C,Body JJ,Bokemeyer C, Reducing the burden of bone metastases: current concepts and treatment options. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2013 Jun;
[PubMed PMID: 23468364]
[9]
Pineda-Moncusí M,Garcia-Giralt N,Diez-Perez A,Servitja S,Tusquets I,Prieto-Alhambra D,Nogués X, Increased Fracture Risk in Women Treated With Aromatase Inhibitors Versus Tamoxifen: Beneficial Effect of Bisphosphonates. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2020 Feb;
[PubMed PMID: 31596961]
[10]
Eastham JA, Bone health in men receiving androgen deprivation therapy for prostate cancer. The Journal of urology. 2007 Jan;
[PubMed PMID: 17161994]
[12]
Drake MT,Clarke BL,Khosla S, Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clinic proceedings. 2008 Sep;
[PubMed PMID: 18775204]
[13]
Van Poznak C,Somerfield MR,Barlow WE,Biermann JS,Bosserman LD,Clemons MJ,Dhesy-Thind SK,Dillmon MS,Eisen A,Frank ES,Jagsi R,Jimenez R,Theriault RL,Vandenberg TA,Yee GC,Moy B, Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Dec 10;
[PubMed PMID: 29035643]
[14]
Saylor PJ,Rumble RB,Tagawa S,Eastham JA,Finelli A,Reddy PS,Kungel TM,Nissenberg MG,Michalski JM, Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 May 20;
[PubMed PMID: 31990618]
[15]
Shapiro CL,Van Poznak C,Lacchetti C,Kirshner J,Eastell R,Gagel R,Smith S,Edwards BJ,Frank E,Lyman GH,Smith MR,Mhaskar R,Henderson T,Neuner J, Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Nov 1;
[PubMed PMID: 31532726]
Level 1 (high-level) evidence
[16]
Eisen A,Somerfield MR,Accordino MK,Blanchette PS,Clemons MJ,Dhesy-Thind S,Dillmon MS,D'Oronzo S,Fletcher GG,Frank ES,Hallmeyer S,Makhoul I,Moy B,Thawer A,Wu JY,Van Poznak CH, Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Mar 1;
[PubMed PMID: 35041467]
[19]
Santini D,Vincenzi B,Caraglia M,Tonini G, A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss. Annals of oncology : official journal of the European Society for Medical Oncology. 2007 Jan;
[PubMed PMID: 17021272]
[20]
Reid IR,Gamble GD,Mesenbrink P,Lakatos P,Black DM, Characterization of and risk factors for the acute-phase response after zoledronic acid. The Journal of clinical endocrinology and metabolism. 2010 Sep;
[PubMed PMID: 20554708]
[21]
Rudran B,Super J,Jandoo R,Babu V,Nathan S,Ibrahim E,Wiik AV, Current concepts in the management of bisphosphonate associated atypical femoral fractures. World journal of orthopedics. 2021 Sep 18;
[PubMed PMID: 34631450]
[22]
Shane E,Burr D,Abrahamsen B,Adler RA,Brown TD,Cheung AM,Cosman F,Curtis JR,Dell R,Dempster DW,Ebeling PR,Einhorn TA,Genant HK,Geusens P,Klaushofer K,Lane JM,McKiernan F,McKinney R,Ng A,Nieves J,O'Keefe R,Papapoulos S,Howe TS,van der Meulen MC,Weinstein RS,Whyte MP, Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2014 Jan;
[PubMed PMID: 23712442]
[23]
Kim DH,Rogers JR,Fulchino LA,Kim CA,Solomon DH,Kim SC, Bisphosphonates and risk of cardiovascular events: a meta-analysis. PloS one. 2015;
[PubMed PMID: 25884398]
Level 1 (high-level) evidence
[24]
Lyles KW,Colón-Emeric CS,Magaziner JS,Adachi JD,Pieper CF,Mautalen C,Hyldstrup L,Recknor C,Nordsletten L,Moore KA,Lavecchia C,Zhang J,Mesenbrink P,Hodgson PK,Abrams K,Orloff JJ,Horowitz Z,Eriksen EF,Boonen S,HORIZON Recurrent Fracture Trial., Zoledronic acid and clinical fractures and mortality after hip fracture. The New England journal of medicine. 2007 Nov 1;
[PubMed PMID: 17878149]
[25]
Kawada K,Minami H,Okabe K,Watanabe T,Inoue K,Sawamura M,Yagi Y,Sasaki T,Takashima S, A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy. Japanese journal of clinical oncology. 2005 Jan;
[PubMed PMID: 15681601]
[26]
Khalafallah AA,Slancar M,Cosolo W,Abdi E,Chern B,Woodfield RJ,Copeman MC, Long-term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study. European journal of cancer care. 2018 Mar;
[PubMed PMID: 28134499]